In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status
- PMID: 38710083
- DOI: 10.7326/J24-0025
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status
Abstract
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204-216. 37952180.
Conflict of interest statement
Comment on
-
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.Circulation. 2024 Jan 16;149(3):204-216. doi: 10.1161/CIRCULATIONAHA.123.067505. Epub 2023 Nov 12. Circulation. 2024. PMID: 37952180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical